CYB-004

Vanda Pharmaceuticals has submitted a New Drug Application to the FDA for Bysanti (milsaperidone), seeking approval for the treatment of acute bipolar I disorder and schizophrenia.

Cybin has launched a Phase 3 clinical trial program, PARADIGM, to evaluate CYB003 as an adjunctive treatment for Major Depressive Disorder (MDD).

Cybin Inc. highlights positive Phase 2 data for CYB003, showing significant efficacy in treating major depressive disorder (MDD).

Cybin's CYB003, a deuterated psilocin drug, demonstrates a 71% sustained remission rate in patients with major depressive disorder (MDD) after 12 months.

Cybin's CYB003 showed 100% response rate and 71% remission rate at 12 months in MDD patients after two 16mg doses, indicating long-term efficacy.